Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...

AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, ...

Moderna is set to reduce its global workforce by roughly 10%, aiming for under 5,000 employees by year's end, as it ...

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...